

Resource Summary Report

Generated by [dkNET](#) on Aug 21, 2026

GIST-T1

RRID:CVCL_4976

Type: Cell Line

Proper Citation

RRID:CVCL_4976

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4976

Proper Citation: RRID:CVCL_4976

Description: Cell line GIST-T1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Gastrointestinal stromal tumor

Defining Citation: [PMID:12004007](#), [PMID:16077968](#), [PMID:19706776](#), [PMID:22665524](#), [PMID:23716303](#), [PMID:25239608](#), [PMID:27997714](#), [PMID:29866822](#), [PMID:32736695](#), [PMID:34738628](#)

Comments: Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: GIST-T1

Synonyms: GIST-T-1, GISTT1, T1

Cross References: ChEMBL-Cells:ChEMBL4482986, ChEMBL-Targets:ChEMBL4483238, Cosmic:1029465, Cosmic:1873953, Cosmic:2607430, Cosmic:2805388, DepMap:ACH-002332, GEO:GSM1701539, GEO:GSM2527248, GEO:GSM2527250, GEO:GSM2527251, GEO:GSM2527316, GEO:GSM2527317, GEO:GSM2527318, GEO:GSM2527319, GEO:GSM3070588, PubChem_Cell_line:CVCL_4976, Wikidata:Q54835846

ID: CVCL_4976

Record Creation Time: 20220427T215902+0000

Record Last Update: 20260815T232841+0000

Ratings and Alerts

No rating or validation information has been found for GIST-T1.

No alerts have been found for GIST-T1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ravegnini G, et al. (2026) Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs). Journal of experimental & clinical cancer research : CR, 45(1).

Schulz T, et al. (2025) Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors???Exploring Their Potential in Targeting GIST. Journal of medicinal chemistry, 68(3), 3238.

Sicinska E, et al. (2024) ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. Cancer research, 84(14), 2247.

Takaki EO, et al. (2024) A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(16), 3603.

Teuber A, et al. (2024) Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA. Nature communications, 15(1), 63.

Teranishi R, et al. (2023) Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. International journal of cancer, 152(12), 2580.

Hemming ML, et al. (2022) MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer discovery, 12(7), 1804.

Hemming ML, et al. (2021) HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1706.

Hemming ML, et al. (2019) Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. *Cancer research*, 79(5), 994.

Smith BD, et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. *Cancer cell*, 35(5), 738.